Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion

This study has been completed.
Sponsor:
Collaborator:
Brahms AG
Information provided by (Responsible Party):
Jonas Rutishauser, Hospital Centre Biel/Bienne
ClinicalTrials.gov Identifier:
NCT00696605
First received: June 10, 2008
Last updated: February 23, 2017
Last verified: February 2017
  Purpose

The are 2 principal goals in this study:

  1. To measure plasma copeptin levels in healthy subjects and to correlate them with plasma AVP concentrations and urine osmolalities in iso-, hypo-, and hyperosmolar states.
  2. To measure plasma copeptin concentrations in patients with chronic renal failure under the same conditions described above, in order to characterize the impact of renal function on circulating copeptin levels in correlation to plasma AVP and urine osmolality.

Condition
Hypoosmolality
Hyperosmolality
Renal Failure

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Prospective
Official Title: Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion

Further study details as provided by Hospital Centre Biel/Bienne:

Enrollment: 20
Study Start Date: July 2008
Study Completion Date: October 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy volunteers; patients with chronic renal failure
Criteria

Inclusion Criteria:

  • chronic renal failure grade I through IV
  • healthy age-matched controls

Exclusion Criteria:

  • chronic renal failure grade V
  • heart failure
  • liver disease
  • nephrotic syndrome
  • anemia (hemoglobin level < 100 g/L)
  • uncontrolled hypertension (systolic BP > 160 mmHg; diastolic BP > 95 mm Hg)
  • coexisting severe disease
  • known thyroid disease
  • known hypocortisolism
  • known hypercortisolism
  • known diabetes insipidus
  • pregnancy
  • lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00696605

Locations
Switzerland
Clinic of Internal Medicine, Hospital Center
Biel/Bienne, Switzerland, 2501
Sponsors and Collaborators
Hospital Centre Biel/Bienne
Brahms AG
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jonas Rutishauser, M.D., Hospital Centre Biel/Bienne
ClinicalTrials.gov Identifier: NCT00696605     History of Changes
Other Study ID Numbers: Swiss AVP-Copeptin Trial
Study First Received: June 10, 2008
Last Updated: February 23, 2017

Keywords provided by Hospital Centre Biel/Bienne:
Hypoosmolality
Hyperosmolality
Copeptin
Vasopressin

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on April 26, 2017